FGF2 and cancer: On this basis, pharmacophore modeling of the interaction of a minimal PTX3-derived FGF-binding pentapeptide with FGF2 has been used for the identification of the first small molecule chemical (NSC12) which acts as an extracellular FGF trap with significant implications in cancer therapy [27].